ALK and non-small cell lung carcinoma: It has been reported that another NSCLC patient, who developed EML4-ALK fusion after becoming resistant to another third-generation EGFR-TKI almonertinib, received crizotinib combined with almonertinib but only had a stable disease status for 1 month (Ren et al., 2022).